Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

374 ARTÍCULOS , VIENDO DEL 316 AL 330

Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer's disease

Ni R, Gillberg PG, Bogdanovic N, Viitanen M, Myllykangas L, Nennesmo I, Långström B, Nordberg A.

Alzheimers Dement. 2017 Apr;13(4):419-430. doi: 10.1016/j.jalz.2016.08.006. Epub 2016 Sep 28.

Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology

Tramutola A, Arena A, Cini C, Butterfield DA, Barone E.

Expert Rev Neurother. 2017 Jan;17(1):59-75. doi: 10.1080/14737175.2017.1246183. Epub 2016 Oct 20.

Concentration of Donepezil in the Cerebrospinal Fluid of AD Patients: Evaluation of Dosage Sufficiency in Standard Treatment Strategy

Valis M, Masopust J, Vysata O, Hort J, Dolezal R, Tomek J, Misik J, Kuca K, Karasova JZ.

Neurotox Res. 2017 Jan;31(1):162-168. doi: 10.1007/s12640-016-9672-y. Epub 2016 Oct 7.

Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial)

Knapp M, King D, Romeo R, Adams J, Baldwin A, Ballard C, Banerjee S, Barber R, Bentham P, Brown RG, Burns A, Dening T, Findlay D, Holmes C, Johnson T, Jones R, Katona C, Lindesay J, Macharouthu A, McKeith I, McShane R, O'Brien JT, Phillips PPJ, Sheehan B, Howard R.

Int J Geriatr Psychiatry. 2017 Dec;32(12):1205-1216. doi: 10.1002/gps.4583. Epub 2016 Oct 13.

Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal

Kuruva CS, Reddy PH.

Drug Discov Today. 2017 Feb;22(2):223-233. doi: 10.1016/j.drudis.2016.10.010. Epub 2016 Oct 27.

Molecular and Therapeutic Targets of Genistein in Alzheimer's Disease

Devi KP, Shanmuganathan B, Manayi A, Nabavi SF, Nabavi SM.

Mol Neurobiol. 2017 Nov;54(9):7028-7041. doi: 10.1007/s12035-016-0215-6. Epub 2016 Oct 28.

Inflammasomes, hormesis, and antioxidants in neuroinflammation: Role of NRLP3 in Alzheimer disease

Pennisi M, Crupi R, Di Paola R, Ontario ML, Bella R, Calabrese EJ, Crea R, Cuzzocrea S, Calabrese V.

J Neurosci Res. 2017 Jul;95(7):1360-1372. doi: 10.1002/jnr.23986. Epub 2016 Nov 8.

Molecular Anti-inflammatory Mechanisms of Retinoids and Carotenoids in Alzheimer's Disease: a Review of Current Evidence

Mohammadzadeh Honarvar N, Saedisomeolia A, Abdolahi M, Shayeganrad A, Taheri Sangsari G, Hassanzadeh Rad B, Muench G.

J Mol Neurosci. 2017 Mar;61(3):289-304. doi: 10.1007/s12031-016-0857-x. Epub 2016 Nov 18.

A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer's disease

Sameem B, Saeedi M, Mahdavi M, Shafiee A.

Eur J Med Chem. 2017 Mar 10;128:332-345. doi: 10.1016/j.ejmech.2016.10.060. Epub 2016 Oct 28.

Pioglitazone for the treatment of Alzheimer's disease

Galimberti D, Scarpini E.

Expert Opin Investig Drugs. 2017 Jan;26(1):97-101. doi: 10.1080/13543784.2017.1265504. Epub 2016 Dec 4.

Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges

Wen MM, El-Salamouni NS, El-Refaie WM, Hazzah HA, Ali MM, Tosi G, Farid RM, Blanco-Prieto MJ, Billa N, Hanafy AS.

J Control Release. 2017 Jan 10;245:95-107. doi: 10.1016/j.jconrel.2016.11.025. Epub 2016 Nov 23.

Sex and gender differences in the treatment of Alzheimer's disease: A systematic review of randomized controlled trials

Canevelli M, Quarata F, Remiddi F, Lucchini F, Lacorte E, Vanacore N, Bruno G, Cesari M.

Pharmacol Res. 2017 Jan;115:218-223. doi: 10.1016/j.phrs.2016.11.035. Epub 2016 Nov 30.

A state of delirium: Deciphering the effect of inflammation on tau pathology in Alzheimer's disease

Barron M, Gartlon J, Dawson LA, Atkinson PJ, Pardon MC.

Exp Gerontol. 2017 Aug;94:103-107. doi: 10.1016/j.exger.2016.12.006. Epub 2016 Dec 12.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias